| 65219 | |
| Alzheimer's disease is a progressive mental deterioration, resulting in loss of memory, confusion and disorientation, and other behavioral problems. Unfortunately, no definitive cure has been developed to treat this disease. Beta-secretase, an important enzyme in the development and onset of Alzheimer's disease, contributes to the formation of amyloid-beta peptides that aggregate in the brain of Alzheimer's patients. Blocking beta-secretase is a potential strategy for the treatment of Alzheimer's disease. Researchers at Purdue University have developed novel compounds that inhibit beta-secretase for Alzheimer's treatment. By focusing on a known dihydroquinazoline scaffold, a series of novel dihydroquinazoline derivatives were synthesized and evaluated. Several compounds in this series were shown to exhibit better beta-secretase cellular inhibitory activity compared to current compounds reported in literature. These compounds show increased potency, improved aqueous solubility, increased metabolic stability, and improved oral bioavailability. Advantages: -Improved beta-secretase cellular inhibition -Increased metabolic stability Potential Applications: -Medical/Health -Pharmaceutical industry |
|
|
|
|
Sep 22, 2011
Utility Patent
United States
8,394,807
Mar 12, 2013
Nov 20, 2009
PCT-Patent
WO
(None)
(None)
Nov 20, 2009
NATL-Patent
Canada
(None)
(None)
Nov 20, 2009
NATL-Patent
European Patent
(None)
(None)
Nov 20, 2009
NATL-Patent
India
(None)
(None)
Nov 20, 2009
NATL-Patent
Japan
(None)
(None)
May 5, 2009
Provisional-Patent
United States
(None)
(None)
Nov 20, 2008
Provisional-Patent
United States
(None)
(None)
(None)
PCT-Patent
WO
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |
